Amgen Q2 FY25: where the revenue came from and where it went
The whole income statement of Amgen for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 6, 2025
Revenue$9.2B
+9% year over year
Gross profit$6.2B
67% margin
Operating profit$2.7B
29% margin
Net profit$1.4B
16% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 9.2 | 100% | +9% |
| Other revenue | 3.4 | 37% | |
| Other products | 1.7 | 18% | +27% |
| Prolia | 1.1 | 12% | −4% |
| Repatha (evolocumab) | 0.7 | 8% | +31% |
| Otezla | 0.6 | 7% | +14% |
| Enbrel | 0.6 | 6% | −34% |
| Xgeva | 0.5 | 6% | −5% |
| Evenity | 0.5 | 6% | +32% |
| Cost of revenue | −3.0 | 33% | |
| Gross profit | 6.2 | 67% margin | +6pp |
| SG&A | −1.7 | 18% | −3pp |
| Other | −1.8 | 20% | +0pp |
| Operating profit | 2.7 | 29% margin | +6pp |
| Interest & other costs | −1.1 | ||
| Tax | −0.1 | ||
| Net profit | 1.4 | 16% margin | +7pp |
107 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest